April 11 (Reuters) - Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas for the U.S. drug developer's experimental prostate cancer drug, Arvinas said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.9 USD | -0.02% | -5.57% | -22.00% |
Apr. 24 | Arvinas, Inc. Appoints Randy Teel as Chief Business Officer | CI |
Apr. 15 | H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
89.05 CHF | +0.20% | +0.12% | 199B | ||
31.9 USD | -0.02% | -5.57% | 2.18B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.00% | 2.18B | |
-3.15% | 102B | |
+1.71% | 96.29B | |
+2.13% | 22.18B | |
-15.87% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.63% | 16.36B | |
+5.92% | 13.97B | |
+34.05% | 12.17B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Novartis licenses Arvinas' cancer drug for up to $1 billion